Physician profile
Bilal A Khan
NPI 1417917436
$5,437.58
in general payments reported to CMS, 2019-2025
31 companies · $16.87 in 2025
The $16.87 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $538 · 2021: $1,397 · 2022: $969 · 2023: $1,501 · 2024: $217 · 2025: $16.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,735.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,537.12 | 2019-2025 | |
| Janssen Biotech, INC. | $479.34 | 2019-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $428.70 | 2019-2023 | Entyvio |
| Ferring Pharmaceuticals INC. | $268.96 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $165.09 | 2019-2023 | Linzess |
| Amgen INC. | $159.39 | 2021-2023 | Avsola, Amjevita |
| Genentech USA, INC. | $147.35 | 2019 | |
| Penumbra, INC. | $136.18 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.98 | 2019-2023 | Trulance |
| Inari Medical, INC. | $119.52 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Regeneron Healthcare Solutions, INC. | $81.89 | 2023 | Dupixent |
| Alfasigma USA, INC. | $79.50 | 2020 | |
| Intercept Pharmaceuticals, INC. | $79.13 | 2022-2023 | Ocaliva |
| Genzyme Corporation | $78.54 | 2022-2023 | |
| Redhill Biopharma INC. | $73.53 | 2020-2023 | Movantik, Talicia, Aemcolo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $70.05 | 2023 | |
| Ucb, INC. | $41.40 | 2019 | |
| Daiichi Sankyo INC. | $40.86 | 2020-2023 | Injectafer |
| Allergan, INC. | $36.29 | 2019-2020 | |
| Organon LLC | $35.21 | 2023 | Renflexis, Hadlima |
| Merck Sharp & Dohme LLC | $33.18 | 2021 | |
| Gilead Sciences, INC. | $31.48 | 2024 | |
| Celgene Corporation | $30.30 | 2021 | |
| Braintree Laboratories, INC. | $28.97 | 2022 | |
| Medtronic, INC. | $26.41 | 2021-2023 | Nexpowder |
| Alnylam Pharmaceuticals INC. | $25.65 | 2023 | Oxlumo |
| Ardelyx, INC. | $23.55 | 2022 | |
| Abbott Laboratories | $18.04 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.01 | 2021 | |
| Shionogi INC | $13.96 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$19,346.90 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.